¡¶¾ìÁµÄãµÄÎÂÈá¡·¶¯ÂþƬµÚ02¼¯Ãâ·Ñ¸ßÇåÔÚÏßԢĿ-ÈÕº«..."/> ÍôС·ÆºÍ Mandy ÄØ£¬ÔÚÕâ´ÎÃÛÔÂÂÃÐеķ粨ÖУ¬ÈôÊÇÄܹ»ÒÔÕæ³ÏµÄ̬¶ÈÃæÁÙ¹«ÖÚµÄÖÊÒÉ£¬ÓÃÏÖʵÑ鶯֤ʵ×Ô¼ºµÄÁµ°®²»ÊÇ×÷Ð㣬ÄÇôËûÃÇ»òÐíÄܹ»»¯½âÕⳡΣ»ú£¬ÉõÖÁ½«Æäת»¯ÎªÌáÉý×Ô¼ºÐÎÏóµÄÆõ»ú¡£"/>
¡¶¡¶¾ìÁµÄãµÄÎÂÈá¡·¶¯ÂþƬµÚ02¼¯Ãâ·Ñ¸ßÇåÔÚÏßԢĿ-ÈÕº«...¡·¾çÇé¼ò½é£ºÍôС·ÆºÍ Mandy ÄØÔÚÕâ´ÎÃÛÔÂÂÃÐеķ粨ÖÐÈôÊÇÄܹ»ÒÔÕæ³ÏµÄ̬¶ÈÃæÁÙ¹«ÖÚµÄÖÊÒÉÓÃÏÖʵÑ鶯֤ʵ×Ô¼ºµÄÁµ°®²»ÊÇ×÷ÐãÄÇôËûÃÇ»òÐíÄܹ»»¯½âÕⳡΣ»úÉõÖÁ½«Æäת»¯ÎªÌáÉý×Ô¼ºÐÎÏóµÄÆõ»úÒ¶ÌìÕ¾Ôڸ߿ÕÖÐÍû×Ų»Ô¶´¦µÄÇàÁúɽÔÚ×Ô¼ºµÄ´ó±¾ÓªÇàÁúɽµÄÉ¢ÐÞ²¢Ã»ÓÐÒþ²Ø×Ô¼ºµÄÆøÏ¢ÒÔÊÇÈÃËûºÜÈÝÒ×¾Í̽²éÇåÎúÇàÁúɽÁôÊØµÄÁ¦Á¿¡¶¾ìÁµÄãµÄÎÂÈá¡·¶¯ÂþƬµÚ02¼¯Ãâ·Ñ¸ßÇåÔÚÏßԢĿ-ÈÕº«...ÕÅСǿÎÞÄÎÈ·µ±×ÅÖù×ÓÈÄÓÐÐËÖµÄÉó²ì×ÅÕâÖêËãÊÇʶʱÎñµÄÖ²ÎïÖ®ÒÔÊÇ˵Õ⹤¾ßÊÇÖ²Îï¶ø²»ÊÇÊ÷ľÊÇÓÉÓÚ×ÅÕ⹤¾ßÐÎ×´ºÜÊǹÖÒì²¢²»Ïñ´óÊåÄÇÑùÒ»¸ö¾¢¶ùµÄ³¯Ìì¿ÕÉú³¤¶øÊÇÖ»¹ÜÏòÖܱßÀ©É¢Dr.Ali Bazarbachi: Basically, there are two kinds of breakthroughs in immunotherapy for Hodgkin Lymphoma. We have Brentuximab Vedotin (BV), which is an anti-CD30 antibody-drug conjugate. We also have checkpoint inhibitors, like anti-PD-1, both of which are highly effective in Hodgkin Lymphoma. And actually, they can be used at different stages of treatment of Hodgkin Lymphoma. Part of frontline therapy in combination with chemotherapy, salvage therapy for relapsed patients as a bridge to auto-consolidation after auto-transplant, salvage therapy for relapse after auto-transplant bridge to allo-transplant, and even for relapse after allo-transplant. So, they have changed the landscape of Hodgkin Lymphoma treatment.
¡¶¡¶¾ìÁµÄãµÄÎÂÈá¡·¶¯ÂþƬµÚ02¼¯Ãâ·Ñ¸ßÇåÔÚÏßԢĿ-ÈÕº«...¡·ÊÓÆµËµÃ÷£ºÔڰ˸öºôÎüÖ®ÖÐËûÓëÁõÌι²Õí4ÄêÄê¹ýÁùÑ®ÈÔδȢÁõÌÎ̹ÑÔ£ºÎÒ¶Ô²»ÆðËûÊ×·¢2024-09-02 16:38¡¤ÔƶäÁÄÌå̳
2025-10-19 17:22:24